Trivaris triamcinolone: Phase III data

Researchers at NIH's National Eye Institute and colleagues reported data from a double-blind Phase III trial in 691 patients (854 treated eyes) showing that eyes treated with 0.5 mg intravitreal Lucentis ranibizumab plus prompt or deferred laser therapy had a significant improvement in BCVA score from baseline to 1 year vs. laser therapy alone (9 vs. 3 letters, p<0.001). Eyes treated with 4 mg intravitreal Trivaris plus laser therapy had a non-significant mean gain in BCVA score of 4 letters from baseline vs. laser therapy alone (p=0.31). Two-year visual acuity outcomes were similar to 1-year outcomes. Additionally, elevated intraocular pressure and cataract surgery were significantly more frequent in Trivaris-treated patients vs. the other study arms. Data were published in Ophthalmology. ...